Regeneron Pharmaceuticals Inc (REGN), Questcor Pharmaceuticals Inc (QCOR), Aegerion Pharmaceuticals, Inc. (AEGR): Three Booming Biotech Companies

Some were concerned that Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)’s path to success with Juxtapid would be challenging in the face of competition from Kynamro, another HoFH drug developed by ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) and marketed by Sanofi SA (ADR) (NYSE:SNY). Kynamro’s annual price tag per patient of $176,000 falls well below the $235,000- to $295,000-per-year cost for Juxtapid. However, Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) is counting on having physicians and patients see its drug as the safer option.

Biggest boom of all
Which of these three biotech companies could see shares boom the biggest of all by the end of this year? Possibly Questcor Pharmaceuticals Inc (NASDAQ:QCOR).

The biotech’s shares are still more than 30% below levels reached last September. Fears run aplenty about the possibility that payers will stop reimbursing for use of Acthar. The stock currently has a short interest of nearly 60%. If the strong April results that Questcor Pharmaceuticals Inc (NASDAQ:QCOR) is touting continue into subsequent months, this stock could soar.

My hunch is that the other two biotech companies will have great years, barring any unforeseen crises. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) claims a more solid track to nice gains with Eylea. However, Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) looks to be off to a good start with the launch of Juxtapid. All in all, these booming biotechs seem set to keep the boom going.

The article 3 Booming Biotech Companies originally appeared on Fool.com and is written by Keith Speights.

Fool contributor Keith Speights and The Motley Fool have no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.